Communiqués Relay Therapeutics, Inc.

Actions

RLAY

US75943R1023

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 24/09/2026			Varia. 5j.	Varia. 1 janv.
17,73 ^USD	-1,66 %		-7,61 %	+109,57 %

16/09	Transcript : Relay Therapeutics, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 09:15 AM
10/09	Transcript : Relay Therapeutics, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-08-2026 01:30 PM

Communiqués

01/09	Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September	GL
06/08	Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates	GL
30/07	Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026	GL
27/05	Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June	GL
21/05	Relay Therapeutics Announces Pricing of Public Offering of Common Stock	GL
19/05	Relay Therapeutics Announces Proposed Public Offering of Common Stock	GL
19/05	Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies	GL
06/05	Relay Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
05/05	Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates	GL
29/04	Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026	GL
27/04	Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer	GL
02/04	Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026	GL
16/03	Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026	GL
26/02	Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones	GL
23/02	Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March	GL
19/02	Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026	GL
04/02	Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026	GL
03/02	Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer	GL
03/02	Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer	AQ
12/12	Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025	GL
06/11	Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates	GL
03/11	Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November	GL
03/11	Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November	AQ
30/10/25	Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025	GL
28/08/25	Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September	GL